United States

People: DURECT Corp (DRRX.O)

DRRX.O on Consolidated Issue listed on NASDAQ Global Market

22 Sep 2017
Change (% chg)

$0.04 (+2.37%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Theeuwes, Felix 

Dr. Felix Theeuwes is the Chairman, Chief Scientific Officer of DURECT Corp. He co-founded DURECT in February 1998 and has served as our Chairman and Chief Scientific Officer since July 1998. Prior to that, Dr. Theeuwes held various positions at ALZA Corporation, including President of New Ventures from August 1997 to August 1998, President of ALZA Research and Development from 1995 to August 1997, President of ALZA Technology Institute from 1994 to April 1995 and Chief Scientist from 1982 to June 1997. Dr. Theeuwes holds a D.Sc. degree in Physics from the University of Leuven (Louvain), Belgium. He also served as a post-doctoral fellow and visiting research assistant professor in the Department of Chemistry at the University of Kansas and has completed the Stanford Executive Program. Dr. Theeuwes’ scientific expertise in drug delivery and pharmaceutical industry experience and the unique perspective he has as the Company’s co-founder and its Chief Scientific Officer are among the qualifications he brings to the Board and his service as a Director of the Company.

Basic Compensation

Total Annual Compensation, USD 277,452
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 469,923
Fiscal Year Total, USD 747,375

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --